Puma Biotechnology's Total Assets for the quarter that ended in Mar. 2024 was $214.1 Mil.
During the past 12 months, Puma Biotechnology's average Total Assets Growth Rate was -14.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -3.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 6.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 27.20% per year.
During the past 13 years, Puma Biotechnology's highest 3-Year average Total Assets Growth Rate was 119.90%. The lowest was -3.70%. And the median was 20.20%.
The historical data trend for Puma Biotechnology's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Puma Biotechnology's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology (NAS:PBYI) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Puma Biotechnology's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Puma Biotechnology Total Assets Related Terms
Thank you for viewing the detailed overview of Puma Biotechnology's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Puma Biotechnology (Puma Biotechnology) Business Description
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PBYI has been successfully added to your 